Clinical Trials on Gallbladder Adenocarcinoma

Total 9978 results

National Cancer Institute (NCI)
Pontificia Universidad Catolica de Chile

Completed

Initial Study of Gallbladder Cancer in Chile

Gallbaldder Cancer

Chile
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Hoffmann-La... and other collaborators

Completed

Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

Biliary Tract Cancer | Gallbladder Adenocarcinoma

United States
Massachusetts General Hospital
Sanofi; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer

Biliary Tract Cancer | Gallbladder Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Hilar Cholangiocarcinoma | Recurrent Gallbladder Carcinoma | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Gallbladder Adenocarcinoma | Recurrent Extrahepatic Bile Duct Carcinoma | Extrahepatic Bile Duct Adenocarcinoma | Gallbladder Adenocarcinoma With Squamous... and other conditions

United States
National Cancer Institute (NCI)

Completed

S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the Gallbladder | Adenocarcinoma of the Gallbladder | Adenocarcinoma With... and other conditions

United States
West Virginia University

Recruiting

Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma

Gallbladder Adenocarcinoma

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Malignant Gastrointestinal Neoplasm | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Gallbladder Carcinoma | Stage IV Gallbladder Cancer | Stage IV Gastric Cancer | Stage IIIA Gallbladder Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

Malignant Neoplasm | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adenocarcinoma of the Gallbladder | Adenocarcinoma of the Extrahepatic Bile Duct

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

Unspecified Adult Solid Tumor, Protocol Specific | Localized Gallbladder Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma of the Gallbladder

United States
University of Nebraska
National Cancer Institute (NCI); Adherex Technologies, Inc.

Completed

ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer

Pancreatic Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IVA Pancreatic Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gallbladder Cancer | Stage IIIB Gallbladder Cancer | Stage IVA Gallbladder Cancer | Stage IVB Gallbladder Cancer | Gallbladder Adenocarcinoma and other conditions

United States
junya mita

Completed

Poorly Differentiated Adenocarcinoma With Signet Ring Cells of the Gallbladder Producing a High Level of Alpha-fetoprotein: a Case Report

Gallbladder Cancer

Japan
National Cancer Institute (NCI)

Active, not recruiting

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Recurrent Gallbladder Carcinoma | Metastatic Gallbladder Carcinoma | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Recurrent Intrahepatic Cholangiocarcinoma | Metastatic... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

TAS-102 in Treating Advanced Biliary Tract Cancers

Cholangiocarcinoma | Stage III Gallbladder Cancer AJCC v7 | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IV Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage IVB Gallbladder Cancer AJCC v7

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.

Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

China
National Cancer Institute (NCI)

Withdrawn

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Cancer | Stage II Gallbladder Cancer | Stage IIIA Gallbladder Cancer | Stage IIIB Gallbladder... and other conditions
Rigshospitalet, Denmark
Aarhus University Hospital

Completed

Avastin and Tarceva for Upper Gastrointestinal Cancers

Cholangiocarcinoma | Gallbladder Cancer

Denmark
Herlev and Gentofte Hospital

Recruiting

Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer (CHOCA)

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Denmark
Washington University School of Medicine

Completed

Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer

Cholangiocarcinoma | Gallbladder Cancer

United States
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Completed

A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC (BTC)

Cholangiocarcinoma | Adenocarcinoma of Gallbladder

Taiwan
Hellenic Cooperative Oncology Group
GlaxoSmithKline

Terminated

Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer

Cholangiocarcinoma | Gallbladder Carcinoma | Biliary Carcinoma

Greece
AIO-Studien-gGmbH
Servier

Completed

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (NALIRICC)

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma Advanced

Germany
The Christie NHS Foundation Trust

Completed

ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers (ABC-08)

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer | Ampullary Cancer

United Kingdom
The Christie NHS Foundation Trust
Cancer Research UK

Completed

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers (ABC06)

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer | Ampullary Cancer

United Kingdom
CHA University
Dong-A Pharmaceutical

Recruiting

Biomarker Discovery in Patients With Advanced Biliary Tract Cancer

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of
Indiana University School of Medicine

Terminated

Storage of Bile From Routine Procedures to Study Risk Factors

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

United States
Asan Medical Center
Samsung Medical Center

Active, not recruiting

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer (DEBATE)

Cholangiocarcinoma | Biliary Tract Neoplasms | Gallbladder Cancer

Korea, Republic of
University of Miami

Terminated

A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

United States
M.D. Anderson Cancer Center
Sanofi-Synthelabo

Completed

Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma

Cancer of the Gallbladder | Cancer of the Biliary Tract

United States
Sun Yat-sen University

Active, not recruiting

Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer (ACCORD)

Biliary Tract Cancer | Gallbladder Cancer | Extrahepatic Cholangiocarcinoma

China
University of Southern California
National Cancer Institute (NCI); Van Andel Research Institute

Active, not recruiting

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Recurrent Gallbladder Carcinoma | Unresectable Gallbladder Carcinoma | Recurrent Hepatocellular Carcinoma and other conditions

United States
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

Gastrointestinal Cancer | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder... and other conditions

United States
Shanghai Jiao Tong University School of Medicine
RenJi Hospital; Huashan Hospital; Ruijin Hospital; Eastern Hepatobiliary Surgery... and other collaborators

Unknown

Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct

China
Seoul National University Hospital
DXOME CO., LTD.

Recruiting

Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer

Pancreatic Cancer | Cholangiocarcinoma | Gallbladder Cancer

Korea, Republic of
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of, United States, Taiwan, China, Argentina, Australia, Brazil, Chile, France, Germany, Italy, Japan, Poland, Spain, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage IVB Gallbladder Cancer AJCC v7 | Stage III Intrahepatic Cholangiocarcinoma AJCC v7 | Stage... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Intrahepatic Cholangiocarcinoma | Gallbladder Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Malignant Neoplasm in the Peritoneum | Distal Bile Duct Adenocarcinoma | Stage IV Distal Bile Duct Cancer AJCC v8 | Stage IV Intrahepatic Bile Duct Cancer AJCC v8 | Stage IVB Gallbladder...

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of, United States, Taiwan, Italy, France, China, Japan, Spain, United Kingdom
Yonsei University

Unknown

A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction

HCC | Pancreatic Cancer | Cholangiocarcinoma | Gallbladder Cancer | AOV Cancer

Korea, Republic of
Shanghai Jiao Tong University School of Medicine
RenJi Hospital; Huashan Hospital; Ruijin Hospital; Eastern Hepatobiliary Surgery...

Unknown

Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct

China
Shanghai Jiao Tong University School of Medicine
RenJi Hospital; Huashan Hospital; Ruijin Hospital; Eastern Hepatobiliary Surgery... and other collaborators

Unknown

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

Cholangiocarcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Gallbladder Cancer AJCC v7 | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IV Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage... and other conditions

United States
Simcere Pharmaceutical Co., Ltd
Eastern Hepatobiliary Surgery Hospital

Unknown

A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer

Bile Duct Cancer | Gallbladder Cancer

China
University of Chicago
National Cancer Institute (NCI)

Completed

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage IV Pancreatic... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Malignant Solid Neoplasm | Cholangiocarcinoma | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Stage III Gallbladder Cancer AJCC v8 | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic...

United States
Washington University School of Medicine

Completed

A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers

Pancreatic Cancer | Gallbladder Cancer | Ampullary Cancer | Cholangiocarcinoma Cancer

United States
National Cancer Institute (NCI)

Completed

Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer

Stage II Gallbladder Cancer | Stage IIIA Gallbladder Cancer | Stage IIIB Gallbladder Cancer | Stage IVA Gallbladder Cancer | Stage IVB Gallbladder Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery

Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the Gallbladder

United States, Canada
National Cancer Institute (NCI)

Completed

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Neoplasms | Liver Cancer | Gallbladder Cancer

United States
Wuhan Union Hospital, China

Not yet recruiting

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Carcinoma | Intrahepatic Cholangiocarcinoma | Gallbladder Cancer | Immunotherapy | Tislelizumab | Surufatinib | Angiogenesis Inhibitors | Antineoplastic Agents, Immunological

Clinical Trials on Gallbladder Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations